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A B S T R A C T
Since nuclear factor of activated T cells (NFAT) was ﬁrst identiﬁed as a transcription factor in T cells, various
NFAT isoforms have been discovered and investigated. Accumulating studies have suggested that NFATs
are involved in many aspects of cancer, including carcinogenesis, cancer cell proliferation, metastasis,
drug resistance and tumor microenvironment. Different NFAT isoforms have distinct functions in differ-
ent cancers. The exact function of NFAT in cancer or the tumor microenvironment is context dependent.
In this review, we summarize our current knowledge of NFAT regulation and function in cancer devel-
opment and treatment. NFATs have emerged as a potential target for cancer prevention and therapy.
© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
Nuclear factor of activated T cells (NFAT) was ﬁrst identiﬁed as
a transcription factor nearly three decades ago. NFAT was original-
ly found in nuclear extracts from activated T cells. Shaw et al.
previously reported that NFAT binds to the interleukin-2 (IL-2) pro-
moter to activate T cells [1]. NFAT was not well studied until the
development of immunosuppressants such as cyclosporine A (CsA)
and tacrolimus (FK506), which block calcineurin activity and inhibit
NFAT nuclear translocation and consequent target gene transcrip-
tion [2]. It was later found that NFAT was also expressed in other
cells and tissues, including muscle, bone, neurons, viscera and skin
[3–6]. Since the ﬁrst research demonstrating the relationship
between NFAT and cancer cells was published [7], more evidence
has emerged to reveal the roles of NFAT in cancer development and
treatment.
NFAT plays crucial role in regulating cancer initiation and pro-
gression, such as proliferation, invasion, migration and angiogenesis
[8–10]. In this review, we focus on the connection between NFATs
and three hallmarks of cancer: drug resistance, metastasis and the
tumor microenvironment [11]. In addition, we also review the func-
tion of NFAT in carcinogenesis, cell proliferation, and the potential
NFAT therapeutics. Insights into NFAT functions will help to elucidate
the NFAT signaling axis mechanism and develop cancer therapies.
The NFAT family and regulation
There are ﬁve NFAT family members, known as NFAT1 (NFATc2/
NFATp), NFAT2 (NFATc1/NFATc), NFAT3 (NFATc4), NFAT4 (NFATc3/
NFATx) and NFAT5 (tonicity enhancer binding protein) [4,12]. NFAT
proteins contain an amino-terminal transactivation domain (TAD)
and a carboxy-terminal domain. NFAT1-4 has two additional con-
served domains, the Rel-homology region (RHR) and NFAT homology
region (NHR). RHR is similar to the DNA-binding domain of the Rel
family (also known as nuclear factor-κB family), and NHR is a reg-
ulatory domain with the calcineurin-binding site. Thus, the Ca2+/
calcineurin pathway regulates NFAT1-4. In contrast, NFAT5 can’t be
activated by calcineurin, as it lacks an NHR [13,14] (Fig. 1A).
In resting cells, the NHR is heavily phosphorylated at serine resi-
dues within several conserved serine-rich sequence motifs (SRR-1,
SPxx repeat, and SRR-2), which can be dephosphorylated by several
types of stimulation [15]. When dephosphorylated, the nuclear lo-
calization sequence (NLS) within NFAT is exposed, resulting in the
protein’s nuclear translocation. In the nucleus, NFAT cooperates with
other transcription factors, such as activator protein 1 (AP1, Fos-
Jun complexes), GATA4, MEF families and forkhead box P3 (FOXP3),
to initiate target gene transcription [16–18]. NHR rephosphorylation
leads to nuclear export signal (NES) exposure and NLS masking,
leading to NFAT translocation from the nucleus to the cytoplasm
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[19]. This reversible phosphorylation controls NFAT nuclear and cy-
toplasmic shuttling to switch its transcriptional activity.
NFAT is primarily activated by store-operated calcium entry via
calcium release-activated calcium (CRAC) channels. The CRAC chan-
nels include the CRAC channel protein 1 (ORAI1) and stromal
interactionmolecule 1 (STIM1) in non-excitable cells [20–23]. Phos-
pholipase Cγ (PLCγ) activation initiates Ca2+ mobilization. Ligand
binding to cell surface receptors, such as immunoreceptors, recep-
tor tyrosine kinases andG-protein-coupled receptor (GPCR), induces
PLCactivationandsubsequentphosphatidylinositol-4, 5-bisphosphate
(PIP2) hydrolysis into diacylglycerol (DAG) and inositol trisphosphate
(IP3). IP3 binds to the Ca2+-permeable IP3 receptor (IP3R) on the en-
doplasmic reticulum(ER)membrane and stimulates Ca2+ release from
the stores into the cytosol. Subsequently, STIM1 senses the de-
crease in ER Ca2+, which then forms oligomers andmoves to the ER–
plasma membrane junction, where it gates the plasma membrane
calciumchannelORAI1. This STIM1–ORAI1 interaction induces a con-
formational change in ORAI1, resulting in a persistent rise in
intracellular Ca2+ concentration. In addition to the STIM–ORAI system,
there are other Ca2+ channels, including voltage-gated Ca2+ and tran-
sient receptor potential ion channels, which are also involved in Ca2+
inﬂux across the plasmamembrane into the cytoplasm [24,25]. The
increased cytoplasmic Ca2+ leads to activation of the Ca2+ sensor
calmodulin (CaM) and CaM further activates the phosphatase
calcineurin [4,26]. As shown in Fig. 1B, calcineurin consists of a
catalytic subunit A (CnA) and a regulatory subunit B (CnB). The CnA
contains a phosphatase catalytic domain, a CnB-binding domain, a
calmodulin-binding domain and a carboxy-terminal auto-inhibitory
domain (AID) [26,27]. Under resting condition, theAID interactswith
the calmodulin-binding domain to inhibit its phosphatase activity.
In the activated state, increased cytoplasmicCa2+ concentration assists
calmodulin in displacing the AID and promotes CnB binding to CnA
by activating Ca2+-binding EF-hand motifs in the CnB. These events
ultimately lead to calcineurin activation. The activated calcineurin
dephosphorylatesmultiple phospho-residues in NFATNHR, leading
to NFAT cytoplasmic–nuclear traﬃcking. Thus, calcineurin plays a
key role in NFAT dephosphorylation [10,28].
In addition to promoting nuclear translocation, calcineurin keeps
NFAT dephosphorylated and constitutively activated in the nucleus.
Therefore, calcineurin inhibition could be an effective way to promote
NFAT nuclear export and cytoplasmic retention. CsA and FK506
inhibit calcineurin by binding to its CnB domain. Both compounds
arewidely used as immunosuppressants in the clinic, mainly in organ
transplantation and dermatology. In addition, there are several en-
dogenous calcineurin inhibitors such as Down’s syndrome candidate
region 1 (DSCR1), calcineurin-binding protein 1 (CABIN1) and
A-kinase anchor protein 79 (AKAP79) [29–31]. Interestingly, DSCR1
is upregulated in patients with Down’s syndrome, and these pa-
tients are less predisposed to malignancy [32]. It was later found
that DSCR1 suppresses tumor growth by inhibiting the calcineurin
Fig. 1. General structure of NFAT and calcineurin. (A) NFAT proteins consist of the Rel-homology region (RHR), the NFAT homology region (NHR) and a C-terminal domain,
while NFAT5 doesn’t possess the NHR. The NHR contains an N-terminal transactivation domain (TAD), the calcineurin binding site, the nuclear localization sequence (NLS)
and the nuclear export signal (NES). It also harbors several serine-rich motifs including SRR1, SRR2, SP1, SP2 and SP3. The RHR comprises the DNA binding domain and the
recognition points with other transcriptional binding partners such as Fos and Jun. (B) The calcineurin protein has two subunits calcineurin A (CnA) and calcineurin B (CnB).
CnA contains a phosphatase catalytic domain and a regulatory domain, the latter owns a CnB-binding domain, a calmodulin-binding domain and an auto-inhibitory domain
(AID). CnB has a main latch region with four Ca2+-binding EF-hand motifs, which can be recognized by immunosuppressive complexes and competitively binds to CnA.
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pathway [33]. Additionally, blocking targets upstream of the Ca2+/
calcineurin/NFAT pathway by inhibiting STIM1/ORAI1 or other Ca2+
channels could be an alternative approach in calcineurin inhibition.
In addition to calcineurin, several serine/threonineprotein kinases
that regulate NFAT have been identiﬁed. These kinases are gener-
ally classiﬁed into two classes: export and maintenance kinases.
Export kinases rephosphorylate NFAT in the nucleus to induce its
relocation to the cytoplasm, while maintenance kinases keep NFAT
fully phosphorylated and keep them in the cytoplasm. Glycogen syn-
thase kinase 3β (GSK3β) phosphorylates the SP2motif of NFAT1 and
the SP2/3 of NFAT2 [34]. NFAT phosphorylation by protein kinase A
(PKA) or the dual speciﬁcity tyrosine phosphorylation-regulated
kinases (DYRKs) is a prerequisite for GSK3β phosphorylation [35].
PI3K/Akt signaling can phosphorylate and inhibits GSK3β, and it is
oneof themosthighly affectedpathways in cancer cells [36].However,
it has alsobeen reported thatGSK3βprotectsNFAT1 fromE3-ubiquitin
ligaseMDM2-mediatedproteolysis [37,38].Mitogen-activatedprotein
kinases (MAPKs), which are excessively activated in human carci-
noma, promote NFAT cytoplasmic translocation. P38 MAPKs
selectively phosphorylate Ser168 and Ser170 in NFAT3’s NHR, and
Jun N-terminal kinase (JNK) phosphorylates the calcineurin-
targeting domain of NFAT2 and NFAT4 [39,40]. There are also
regulators that have both maintenance and export kinase func-
tions, such as DYRKs and casein kinase 1 (CK1). The DYRK family
was ﬁrst discovered in a genome-wide small interference RNA screen
in Drosophila melanogaster [35], and it is composed of two family
members:DYRK1andDYRK2.DYRK1works as anNFATexport kinase,
while DYRK2 functions as a maintenance kinase. Both can directly
phosphorylate NFAT1’s SP3 motif. CK1 functions as a maintenance
kinase by phosphorylating the SRR1 motif and as an export kinase
by docking at a conserved motif near NFAT1’s N-terminus [41].
Interestingly, there is another type of NFAT kinase, which can
phosphorylate NFAT and enhance their transcriptional activity.
Cot/Tpl2 kinase and the PKC pathway promote NFAT1 nuclear trans-
location by phosphorylating Ser53 and Ser56 of the N-terminal TAD.
CsA does not inhibit this transactivation, which indicates that NFAT1
can be activated independent of calcineurin [42,43]. Another recent
study has revealed that human vaccinia-related kinase 2 (VRK2) has
similar functions. VRK2 phosphorylates Ser32 in the N-terminal TAD
followed by calcineurin activation [44].
In addition to NFAT kinases, caspase 3 has been shown to cleav-
age two potential sites in the NFAT1 TAD [45]. Poly-ADP-ribose
polymerase 1 (PARP1) promotes NFAT stability and transcrip-
tional activity in T cells [46,47]. Post-translational modiﬁcations,
including ubiquitination and sumoylation, alsomodulate NFAT, which
makes the NFAT family’s regulatory network more complex [38,48]
(Fig. 2).
NFATs in tumorigenesis and proliferation
It is well known that carcinogen-induced genetic or epigenetic
aberration leads to tumorigenesis. NFAT is a ubiquitous transcrip-
tion factor in vertebrates, and its dysregulation induces the
expression of various target genes involved in cancer develop-
ment. However, NFAT isoforms have distinct and diverse functions
in the tumorigenic process. Constitutive NFAT2 activation inhibits
ﬁbroblast cell differentiation and induces malignant transforma-
tion. In contrast, constitutively active NFAT1 induces cell cycle arrest
and apoptosis and inhibits H-rasV12-induced transformation [49].
NFAT1 deﬁcient mice have an increased susceptibility to chemical
carcinogen-induced tumorigenesis. Other carcinogens, including
nickel compounds and asbestos, have been reported to increase NFAT
activity by diverse mechanisms [50–52]. These results suggest that
NFAT1 is a tumor suppressor and NFAT2 is an oncogene. However,
there are also some contradictory reports. In organ-transplant pa-
tients, long-term treatment of CsA or FK506 increases the risk of
skin cancer [53,54]. Constitutive NFAT2 activation induces skin and
ovary cancers in transgenic mice, suggesting that NFAT2 has dual-
characterized effects [49]. Similarly, CsA or FK506 pretreatment
impairs ultraviolet B-induced apoptosis of human keratinocytes [55],
while CsA and FK506 enhanced ultraviolet A-induced human ﬁ-
broblast cell death [56]. These inconsistencies may be because
different cell types express distinct primary NFAT isoforms. Human
keratinocytes may express NFAT1 as its major isoform while ﬁbro-
blasts primarily express NFAT2.
NFATs also regulate mammalian cell proliferation. Constitutive
NFAT2 activation not only induces cell transformation but also pro-
motes colony formation in ﬁbroblasts [57]. Similarly, NFAT2 induces
c-Myc transcription in pancreatic cancer cells and c-Myc interacts
with the NFAT complexes, leading to cyclin D upregulation and
anchorage-independent growth [58]. Additionally, sequential in-
duction of NFAT2 and c-Myc facilitates TGF-β-promoted cell growth
in various cancer cells [59]. NFAT1 suppresses cyclin dependent
kinase 4 (CDK4) and cyclin A2 expression to control lymphocyte cell
cycle and proliferation [60,61]. In NFAT1 and NFAT4 deﬁcient mice,
immune cells are resistant to activation-induced cell death,
hyperactivation and defective Fas ligand production, highlighting
their tumor suppressor activities [62,63]. However, NFAT1 has been
shown to induce MDM2 transcription and inactivate p53 in breast
cancer cells [64]. Baumgart et al. previously report that NFAT1 ex-
pression correlates with advanced stage pancreatic cancer by
silencing the tumor suppressor gene p15 [65]. Taken together, these
data suggest that NFAT1 is a tumor suppressor in untransformed
cells, but may act as an oncogene in cancer cells.
Previous studies also revealed that NFAT2 plays a critical role in
the switch from stem cell dormancy to proliferation. As the down-
stream of bone morphogenetic protein 4, NFAT2 inhibits CDK4 to
maintain skin stem cell dormancy [6]. Another study demon-
strated that constitutively activated NFAT2 leads to signiﬁcant
expansion of CD34+ cells and initiates skin squamous cell-like car-
cinoma [66]. NFAT2 may be involved in acquiring stem cell-like
properties and self-renewal capacity, including tumor cell epithe-
lial to mesenchymal transition (EMT) [67] (Table 1).
NFATs in tumor metastasis
Metastasis is the leading cause of human cancer death. Even in
patients with decades of disease-free survival, metastatic tumors
sometimes recur. It is well known that angiogenesis and
lymphangiogenesis are necessary for cancer metastasis. Cancer cells
become aggressive and motile through EMT, and invade the blood
or lymphatic vessels to circulate [68]. It is estimated that 0.01% of
cancer cells in circulation will survive and initiate new tumor growth
in distant organs [69]. Although the metastatic process is clear, the
molecular mechanism is still unclear. Emerging evidence has sug-
gested that NFATs play important roles in the metastasis process.
NFATs in tumor invasion and migration
Invasion and migration acquisition is the ﬁrst step of cancer me-
tastasis, and it is always combined with EMT [70]. Jauliac et al. ﬁrst
reported that NFAT1 expression promotes breast cancer cell inva-
sion and migration, and wild-type NFAT5 expression only promotes
migration. Meanwhile, NFAT1 and NFAT5 overexpressions have been
found in invasive primary breast cancer cells, and this NFAT1/5
overexpression is accompanied with increased α6β4 integrin ex-
pression [71]. The α6β4 integrin is anchored to hemidesmosomes
and correlates with the actin cytoskeleton in cancer cells. NFATs are
downstream of α6β4 integrin signaling, as α6β4 integrin regu-
lates NFAT5. Another aberrant pathway in breast cancer is the PI3K/
Akt pathway [36]. Although PI3K/Akt activity leads to nuclear NFAT
retention and increased NFAT activity by inhibiting GSK3β, breast
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Fig. 2. The NFAT pathway and regulation. Immunoreceptors, receptor tyrosine kinases (RTKs) and G-protein-coupled receptors (GPCR) activate phospholipase Cγ (PLCγ),
which hydrolyzes phosphatidylinositol-4,5-bisphosphate (PIP2) into diacylglycerol (DAG) and inositol trisphosphate (IP3). IP3 binds to Ca2+-permeable IP3 receptor (IP3R) on
the endoplasmic reticulum (ER) and stimulates Ca2+ release into the cytosol. With the loss of calcium, stromal interaction molecule (STIM) reforms into oligomers and in-
teracts with calcium release-activated calcium channel protein (ORAI), which then induces a sustained inﬂux of extracellular Ca2+. Transient receptor potential (TRP) Ca2+
channels are other ways for Ca2+ entry. Then the calcium sensor protein calmodulin (CaM) is activated by Ca2+ and further activates calcineurin, which dephosphorylates
NFAT, leading NFAT cytoplasmic–nuclear traﬃcking. In the nucleus, NFAT forms dimers or cooperates with other transcription partners to initiate target gene transcription.
Some transcription partners can be activated by RAS/RAF/MEK/ERK signaling. NFAT is also regulated by various NFAT kinases. Glycogen synthase kinase 3β (GSK 3β), dual
speciﬁcity tyrosine phosphorylation-regulated kinases (DYRKs), casein kinase 1 (CK1), mitogen-activated protein kinase (p38 MAPK) and Jun N-terminal kinase (JNK)
rephosphorylate and inactivate NFAT, while human vaccinia-related kinase 2 (VRK2) and Cot kinase cooperating with protein kinase C (PKC) promote NFAT nuclear trans-
location. NFAT could be cleaved by caspase 3 and ubiquitinated by MDM2which is activated via the PI3K/AKT pathway, while poly-ADP-ribose polymerase 1 (PARP1) stabilizes
and activates NFAT. There are also several endogenous calcineurin inhibitors, including Down syndrome candidate region 1 (DSCR1), calcineurin-binding protein 1 (CABIN1),
and A-kinase anchor protein 79 (AKAP79), as well as pharmacological calcineurin inhibitors: cyclosporine A (CsA) and tacrolimus (FK506), which bind to cyclophilin and
FK506 binding protein (FKPB) respectively.
Table 1
NFATs in tumorigenesis and proliferation.
NFAT isoforms Cell types Potential mechanism Reference
NFAT1 3T3 cell Inducing cell cycle arrest and apoptosis, inhibiting H-rasV12-induced transformation and
reducing the risk in carcinogen-induced tumorigenesis.
[49]
T cell Suppressing CDK4 and cyclin A2 and inducing FasL and AICD. [60–62]
Breast cancer Inducing MDM2 transcription and inhibiting p53. [64]
Pancreatic cancer Silencing tumor suppressor gene p15 (INK4b). [65]
NFAT2 3T3, Skin and ovary cells Inhibiting cell differentiation, promoting colony formation, inducing malignant transformation
and CD34+ stem cell expansion.
[49,57]
Colon cancer and pancreatic cancer Inducing expression of c-Myc and cyclin D, and facilitating TGF-β-promoted cell growth. [58,59]
Skin stem cell Maintaining dormancy of stem cells by inhibiting CDK4. [6]
NFAT3 Null
NFAT4 T cell Decreasing lymphoproliferation by inhibiting NFAT2-induced IL-4 expression and increasing AICD. [62,63]
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cancer cells with activated PI3K/Akt signaling show decreased mo-
tility and invasion. Further investigation explains that Akt promotes
NFAT1 ubiquitination exclusively by the E3 ubiquitin ligase MDM2
[38]. Liu et al. and Chen et al. also ﬁnd that NFAT1 is overexpressed
in human lung cancer cells and NFAT1 knockdown inhibits cell in-
vasion and migration [72,73].
Mechanistically, NFATs are transcription factors for invasion and
migration-associated genes, such as cyclooxygenase-2 (COX-2) and
autotaxin. NFAT1 induces COX-2 expression, which catalyzes pros-
taglandin synthesis, including prostaglandin E2 (PGE2), in breast
epithelial cells [74]. Knockdown or chemical inhibition of COX-2
limits breast cancer cell invasion. In contrast, COX-2 or PGE2
overexpression enhances cell invasion [74]. Another NFAT target gene
is autotaxin, which converts lysophosphatidylcholine into
lysophosphatidic acid (LPA), and LPA acts as both mitogen and
motogen in breast cancer. Autotaxin is overexpressed in an α6β4/
NFAT-dependent way and facilitates breast cancer cell metastasis
in vitro and in vivo [75].
Furthermore, NFAT1 can initiate glypican-6 (GPC-6) transcrip-
tion, which activates JNK and p38 MAPK through Wnt5A signaling
and increases breast cancer cell invasive migration [76]. However,
as mentioned above, p38 MAPK also functions as an NFAT1 export
kinase. This may provide a feedback and self-regulation of the NFAT-
MAPK loop. NFAT1 hyperactivity may not be completely inhibited
by NFAT kinases, and this ultimately leads to the pro-metastasis phe-
notype. Foldynova-Trantirkova et al. reported that CK1ε mutants
activate the Wnt/Rac1/JNK and NFAT pathways, resulting in de-
creased breast cancer cell adhesion and increased migration [77].
Matrix metalloproteinases (MMPs) are well-known basement mem-
brane proteolytic enzymes that are activated during tumor invasion
[78], and they are induced by NFATs in myocytes, glomerular
mesangial cells and astrocytes [79–81]. One recent study has found
that NFAT1 is overexpressed in glioblastoma multiforme cells, and
its overexpression increases the invasive potential of tumor cells
throughMMP-7 andMMP-9 upregulation [82]. Additional study has
claimed that NFAT2 activation promotes metastasis of mouse bone
tumor cells via MMP-2 upregulation [83].
Interestingly, NFAT3 has an anti-metastatic function in estro-
gen receptor α positive (ERα+) breast cancer cells [84]. NFAT3
cooperates with ERα to prevent cancer cell migration, and it inhib-
its lipocalin 2 expression to reduce cancer cell invasion. Conversely,
NFAT3 downregulation leads to actin reorganization, which corre-
lates with increasedmigration and invasion. Taken together, different
NFAT isoforms have diverse functions, making it more diﬃcult and
complicated to target NFAT in anti-cancer therapies (Fig. 3).
NFATs in tumor angiogenesis and lymphangiogenesis
The most common pathway for cancer metastasis is the human
vessel system, which includes blood and lymphatic vessels. In ad-
dition to providing nutrients and oxygen for tumor proliferation and
survival, tumor neovascularization provides a way for tumor me-
tastasis. Neovascular primitive structure, malformation, blood ﬂow
disturbance and hyperpermeability all contribute to metastasis. In
vertebrates, calcineurin/NFAT signaling is essential for cardiovas-
cular system formation [85,86]. Thus, it is reasonable that NFATsmay
be involved in angiogenesis and lymphangiogenesis, which are es-
sential for cancer dissemination.
Several soluble factors have been identiﬁed to correlate with
tumor angiogenesis, including vascular endothelial growth factor
A (VEGFA), acidic/basic ﬁbroblast growth factor (a-FGF/b-FGF) and
secreted frizzle-related protein 2 (SFRP2) [11,87,88]. VEGFA activates
PLCγ by binding to the VEGF receptor (VEGFR), while FGF23 binds
to FGF receptor 1c (FGFR1c). Both lead to calcineurin/NFAT signal-
ing activation [89]. SFRP2 increases NFAT4 nuclear translocation
through the noncanonical Wnt/Ca2+/NFAT pathway [87]. After they
Fig. 3. NFATs in tumor invasion and migration. The most important acquired property for tumor invasion and migration is the epithelial to mesenchymal transition (EMT).
NFATs are proved to be related to this section as their transcriptional targets are involved. The α6β4 integrin on tumor cells activates NFATs, which transcript multiple target
genes such as cyclooxygenase-2 (COX-2), prostaglandin E2 (PGE2), autotaxin and matrix metalloproteinases (MMPs). COX-2 synthesizes PGE2, while autotaxin catalyzes
lysophosphatidic acid (LPA). Both PGE2 and PLA bind to PGE2 receptor (EP) and LPA receptor (LPAR), respectively, to promote tumor invasion and migration. MMPs promote
the proteolysis of extracellular matrix (ECM), and facilitate tumor cells migrating through the ECM. NFAT3 cooperates with ERα to reduce migration through inhibiting lipocalin
2 (LCN2) expression in breast cancer cell.
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localize to the nucleus, NFATs enhance transcription of some target
genes involved in angiogenesis, such as COX-2, tissue factor (TF) and
caspase-8 inhibitor cellular Fas-associated death domain-like
interleukin 1β-converting enzyme inhibitory protein (c-FLIP). COX-2
plays a pro-angiogenic role by enhancing PGE2 synthesis. COX-2 in-
hibitor or CsA can inhibit angiogenesis in vitro and in vivo. However,
CsA fails to prevent b-FGF-induced angiogenesis, suggesting that
NFAT activation by b-FGF does not require the canonical pathway
[90]. Later, c-FLIP was found to be an angiogenesis enhancer as down-
stream of b-FGF/NFAT1 signaling. Meanwhile, pigment epithelium-
derived factor (PEDF) acts as an inhibitor of FGF-activated NFAT1
by activating JNKs, leading to decrease c-FLIP expression and inhi-
bition of angiogenesis [91]. TF is another crucial angiogenesis initiator
induced by the VEGFA/NFAT pathway [92].
More powerful evidence for NFAT involvement in tumor angio-
genesis lies in animal models and human pathophysiology. The
endogenous calcineurin suppressor DSCR1 and maintenance kinase
DYRK1A are upregulated in Down’s syndrome patients. Baek et al.
previously report that Down’s syndrome could suppress tumor
growth. Using transgenic mice, they found that DSCR1 and DYRK1A
block angiogenesis by inhibiting the VEGFA/calcineurin/NFAT sig-
naling pathway [33]. The congenital disease infantile hemangioma
is also related to VEGFR/NFAT signaling dysregulation [93]. In the
region of disorganized vasculature, VEGFR1 is downregulated in an
NFAT-dependent manner. VEGFR1 downregulation leads to VEGF-
dependent VEGFR2 activation. A subset of these patients harbor
mutations in VEGFR2 or integrin-like receptor TEM8, which forms
a complex with β1 integrin, inhibits integrin/NFAT signaling and
reduces VEGFR1 expression. Conversely, wild-type VEGFR2 or TEM8
overexpression restores the normal phenotype [93].
Lymphatic metastasis is another route for tumor dissemina-
tion. Solid tumors utilize pre-existing lymph vessels or generate new
lymphatic vasculature to reach distant organs. Chen et al. previ-
ously reported that NFAT expression is signiﬁcantly higher in lung
cancer than in adjacent normal lung tissues. Moreover, NFAT1 ex-
pression was signiﬁcantly higher in patients with lymph node
metastasis than without lymph node metastasis. Therefore, posi-
tive NFAT1 expression indicates a poor prognosis in lung cancer [73].
VEGFC and platelet-derived growth factor BB (PDGF-BB) have been
extensively studied in lymphangiogenesis [94,95]. VEGFC and PDGF-
BB co-expression is also related to lymphangiogenesis in lung cancer
[96]. The results above suggest that both the VEGFC/NFAT1 and PDGF/
NFAT1 pathways are involved in tumor lymphangiogenesis. NFAT2
also plays a critical role in lymphatic-valve morphogenesis and pat-
terning [97]. As downstream of VEGFA/VEGFR2 signaling pathway,
it interacts with prospero homeobox 1 (PROX1) or FOXC2 to promote
lymphangiogenic gene transcription, including FGFR3, VEGFR3 and
podoplanin (Fig. 4).
As discussed above, NFATs can facilitate tumor angiogenesis
and lymphangiogenesis. Consequently, NFATs can promote tumor
progression and metastasis. To date, the anti-VEGF antibody and
VEGFR tyrosine kinase inhibitors (TKIs) have been used to inhibit
tumor angiogenesis and lymphangiogenesis, but the result is
not so satisfactory. Due to NFAT’s crucial role in angiogenesis and
lymphangiogenesis, further investigation is required to explore
new effective methods in targeting NFAT and its down or up-
stream genes.
NFATs in tumor survival and drug resistance
Accumulating evidence indicates that the NFAT family is in-
volved in the development of drug resistance to chemotherapeutics
or targeted agents. It has been reported that the dysregulation of
NFAT signaling confers malignant cells with pro-survival potential
under stress conditions. CsA induces apoptosis in rat glioma cells,
which indicates that the calcineurin/NFAT pathway can promote
glioma cell survival [98]. In large B-cell lymphoma (LBCL), NFAT2
is constitutively active and interacts with NF-κB to upregulate their
downstream target gene CD154 and B-lymphoma stimulator (BLyS),
which can maintain lymphoma cell survival. NFAT2 knockdown by
siRNA induces LBCL apoptosis, suggesting that NFAT2 constitutive
activation plays a pivotal role in maintaining LBCL survival [99]. In-
terestingly, NFAT3 acts as a tumor suppressor. It is required in
doxorubicin-mediated apoptosis in human glioma cells, as the NFAT3
target gene tumor necrosis factor α (TNF-α) is required to initiate
caspase-dependent apoptosis [100]. NFAT family members can also
induce caspase-independent apoptosis [101,102].
As discussed above, NFATs have potential pro-survival func-
tions, as tumor cells may develop drug resistance via NFAT pathway
activation. ABT-737 induces cancer cell apoptosis by binding to anti-
apoptotic Bcl-2 family member proteins. But Bcl-2-A1 is upregulated
by TCR/calcineurin/NFAT pathway in activated T lymphocytes or ABT-
737-resistant chronic lymphocytic leukemia. Bcl-2-A1 is a Bcl-2
family member with an anti-apoptotic function. Therefore, block-
ing Bcl-2-A1-dependent anti-apoptotic signaling via CsA is critical
to prevent ABT-737 resistance [103].
Imatinib is the ﬁrst targeted drug that greatly improves the
outcome of Philadelphia chromosome positive (Ph+) chronic myeloid
leukemia (CML) patients by inhibiting Bcr–Abl [104]. Unfortu-
nately, these cancers often acquire imatinib resistance and become
more aggressive. A recent study revealed that the Wnt/Ca2+/NFAT
pathway is involved in imatinib resistance. Wnt5A-bound Frizzled
(FZD) binds to GPCR and activates phospholipase C, which acti-
vates NFAT2. The NFAT2 target gene IL-4 promotes CML cell survival
upon Bcr–Abl Inhibition. Wnt/Ca2+/NFAT signaling inhibition sen-
sitizes Ph+ leukemia cells to Bcr–Abl inhibitors, including imatinib
and the second-generation inhibitor dasatinib in vitro and in vivo
[105]. Griesmann et al. reported that the Wnt/Ca2+/NFAT pathway
alsomediates pancreatic cancer cell resistance to drug-induced apop-
tosis. Wnt5A knockdown leads to a remarkable increase in
gemcitabine-induced apoptosis [106]. As a downstream Wnt5A
target, NFAT1 functions in an anti-apoptosis mechanism.
Another successful targeted drug is the ﬁrst-generation of epi-
dermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI),
which greatly helps in the treatment of lung cancer patients with
EGFR sensitive mutations [107]. Geﬁtinib and erlotinib inhibit the
EGFR signaling cascade by reversibly binding to EGFR’s adenosine
triphosphate binding sites. However, EGFR-TKIs have similar limi-
tations as Bcr–Abl inhibitors. Nearly all patients acquired resistance
to TKIs via diverse mechanisms, such as a secondary T790M mu-
tation, c-Met ampliﬁcation or PI3K mutation. The second-
generation TKI afatinib, which irreversibly binds to EGFR still could
not overcome the effect of the T790M mutation. Recently, signal
transducer and activator of transcription 3 (STAT3) activation has
been shown to be involved in TKI resistance [108,109]. STAT3
induces Wnt5A activation, which can stimulate the noncanonical
Wnt/Ca2+/NFAT pathway, as discussed above. Moreover, NFAT2 con-
stitutive activation induces autocrine of growth factors, which can
activate STAT3 in turn [110]. Interestingly, nuclear NFAT2 can co-
operate with STAT3 to control IL-6, IL-4 and other cytokine
expressions [111]. This feedback loop promotes cancer cell surviv-
al under stress, such as anti-cancer drug treatment. Our preliminary
study also shows that CsA greatly enhances geﬁtinib-induced apop-
tosis in both EGFR sensitive and resistant cell lines through STAT3
inhibition (unpublished data). The BRAF inhibitor vemurafenib
andMEK inhibitor trametinib provide clinically signiﬁcant improve-
ments in melanoma patients [112,113]. Recent reports have
demonstrated that NFAT inhibition augments vemurafenib and
trametinib anti-cancer effects [114,115]. Spreaﬁco et al. have found
that combination treatment with CsA reverses resistance to the
MEK inhibitor selumetinib in a patient-derived tumor xenograft
model of colorectal cancer [116] (Table 2).
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NFATs in the tumor microenvironment
Since Stephen Paget proposed the famous ‘seed and soil’ hypoth-
esis, the tumormicroenvironment has been a focus in cancer research
[117]. It is now well recognized that the tumor microenvironment
is involved in every stage of cancer, including tumorigenesis, cancer
proliferation, metastasis and drug resistance [69]. The tumor mi-
croenvironment is a complex system composed of endothelial cells,
ﬁbroblasts, pericytes, muscle cells, immune cells and their precur-
sors. It is an integral and essential component of cancer [118].
Therefore, it is necessary to treat both tumor cells and the tumormi-
croenvironment. Themolecularmechanismof the interaction between
tumor cells and its microenvironment remains elusive. Recently,
several studies have demonstrated that NFATs exert important func-
tions in the tumormicroenvironment, which signiﬁcantly affect cancer
initiation and development.
Numerous cytokines are involved in tumorigenesis, angiogen-
esis and metastasis. NFAT signaling activation in tumor cells results
in inﬂammatory chemokine production, which can recruit inﬂam-
matory cells, including mast cells, neutrophils and monocytes, to
Fig. 4. NFATs in tumor angiogenesis and lymphangiogenesis. Neovascular and neolymphatic are two main approaches for tumor cells to detach from initial location and
spread to distant organs. Vascular endothelial growth factor (VEGF), ﬁbroblast growth factor (FGF), secreted frizzle-related protein 2 (SFRP2) and platelet-derived growth
factor BB (PDGF-BB) are secreted into ECM by various cells, including tumor cells, ﬁbroblasts, endothelial cells and precursors. On the neovascular side, VEGFA and FGF
bind to each receptor, while SFRP2 cooperates with Wnt to activate non-canonical Wnt/Ca2+/NFAT pathway. Both lead to the expression of angiogenesis factors, including
COX-2, PGE2, tissue factor (TF) and cellular Fas-associated death domain-like interleukin 1β-converting enzyme inhibitory protein (c-FLIP). Pigment epithelium-derived factor
(PEDF) inhibits NFAT through JNK signaling, and indirectly attenuates the angiogenesis induced by c-FLIP. On the neolymphatic side, VEGFC, FGF and PDGF-BB promote
NFAT nuclear translocation, and NFAT interacts with prospero homeobox protein 1 (PROX1) or FOXC2 to transcript neolymphatic-related genes, such as FGFR, VEGFR and
podoplanin.
Table 2
NFATs in drug resistance.
Compounds NFAT isoforms Potential mechanism Tumor types Reference
Doxorubicin NFAT3 Caspase-dependent apoptosis initiated by NFAT3-activated TNF-α. Glioma [100]
Gemcitabine NFAT1 Wnt5A/NFAT1 pathway inhibition increases apoptosis. Pancreatic cancer [106]
Dasatinib and Imatinib NFAT1 IL-4 activated by NFAT1 leads to treatment failure. CML [105]
ABT-737 NFAT Bcl-2-A1 induces drug resistance by calcineurin/NFAT pathway CML [103]
Geﬁtinib and Erlotinib NFAT2 STAT3 is activated by NFAT2 in various approaches. Lung cancer [110,111]
PD0325901 and vemurafenib NFAT1 Enhanced apoptosis by inhibiting calcineurin/NFAT1 pathway Melanoma [114,115]
Selumetinib NFAT1 Increased apoptosis via Inhibiting Wnt/Ca2+/NFAT1 signaling. Colorectal cancer [116]
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the tumor [119]. Thus a feedforward loop forms between inﬂam-
mation, the immune response and cancer. CXCL12 and CCL21 are
chemokines that are upregulated in advanced breast cancer, and
these chemokines act as a chemotactic factor to promote breast
cancer cell invasion [120,121]. Likewise, macrophages inﬁltrate into
the tumor microenvironment and secrete epidermal growth factor
(EGF) and colony-stimulating factor 1 (CSF1) to facilitate tumor pro-
liferation and migration [122]. NFATs can induce CSF1 in both
immune cells and tumor cells, indicating a dual effect of NFATs in
tumor progression.
Recently, there are some direct pieces of evidence indicating
that NFAT signaling establishes the tumorigenic microenviron-
ment in vivo. In inducible constitutively active NFAT2 transgenic
mice, spontaneous cancers were found in the skin and ovary. In-
triguingly, both cells expressing constitutively active NFAT2 and
neighboring wild-type cells upregulated c-Myc and STAT3 in skin
and ovary tumors. This phenomenon suggests that NFAT2 consti-
tutive activation affects the microenvironment and further affects
the neighboring cells. Meanwhile, several cytokines and cytokine
receptors are upregulated and contribute to the inﬂammatory
microenvironment. In conclusion, NFAT2 activation possesses both
cell autonomous and cell non-autonomous mechanisms for estab-
lishing the tumor microenvironment in situ [66]. Studies have also
been performed examining the microenvironment of the pre-
metastatic site or niche. Loss of DSCR1, an endogenous calcineurin
inhibitor, leads to excessive calcineurin/NFAT/angiopoietin-2 (ANG-2)
pathway activation in lung endothelium and the establishment of
lung metastasis [123]. Increased VEGF level in the lung microen-
vironment triggers calcineurin/NFAT/ANG-2 signaling activation and
promotes angiogenesis in the pre-metastatic niche. Although there
was no difference in the numbers of lungmetastases in NFAT1 knock-
out mice, the tumors are smaller in size [124]. Loss of NFAT1 reduces
transforming growth factor β (TGF-β) expression and recruits more
mononuclear cells.
In addition, NFAT1 has been reported to promote tumor-
induced T-cell anergy [125]. As themain antitumor immune response
character, T cells are attenuated by the tumor-associated immuno-
suppressive microenvironment. Normally, NFAT activation
results in T cell excitation. In B16 melanoma or TC-1 lung cancer
bearing animals, NFAT1 deﬁcient mice harbor more effective
Fig. 5. NFATs in tumor microenvironment. The tumor microenvironment is a complex system which is involved in all aspects discussed above, including tumor migration,
angiogenesis and drug resistance. Here we brieﬂy focus on inﬂammatory cells and other neighboring cells. NFAT facilitates cytokines secreted into the tumor microenvi-
ronment, which induce inﬂammatory cells inﬁltrating in the tumor microenvironment. Macrophages produce epidermal growth factor (EGF) and colony-stimulating factor
1 (CSF1) for tumor proliferation and migration. T cells are induced into an anergic condition due to decreased interleukin 2 (IL-2) and interferon-γ (IFN-γ) by NFAT1. NFAT
promotes the expression of signal transducer and activator of transcription 3 (STAT3), c-Myc, MMPs and transforming growth factor-β (TGF-β) in neighboring cells at primary
tumor location, while in pre-metastatic niche, VEGF activates the calcineurin/NFAT signaling and leads to the high level of angiopoietin-2 (ANG-2), which induces the
neovascularization for the circulating cancer cell (CTC) settling down.
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tumor-inﬁltrating CD4+ T cells, which can inhibit tumor growth.
These NFAT1−/− CD4+ T cells produce more IL-2 and interferon-γ
(IFN-γ) than wild-type mice, and are resistant to tumor-induced
anergy. Interestingly, NFAT1 depletion does not affect T-cell acti-
vation, likely due to a compensatory effect by NFAT2 (Fig. 5).
Targeting the NFAT pathway for cancer therapy
As discussed above, the two classical calcineurin inhibitors CsA
and FK506 are widely used as immunosuppressant in organ recipi-
ents. CsA binds to the immunophilin protein cyclophilin, while FK506
binds to FK binding protein (FKBP). Both drug–immunophilin com-
plexes directly interact with calcineurin and inhibit its phosphatase
activity, leading to NFAT inactivation [2,126]. The peptide called VIVIT
prevents the interaction between calcineurin and NFATs to block
NFAT activation [127]. VIVIT has more potent anticancer function
in vitro and in vivo [128]. However, the chemical inhibitors and
peptide target proteins upstream of NFATs, which will lead to broad
NFAT inhibition. Therefore, the clinical usage of these NFAT inhibi-
tors is accompanied by various toxicities [129,130]. Similar novel
compounds have been synthesized that reduce complications and
increase eﬃciency [131]. The endogenous calcineurin inhibitor
DCSR1 may be an alternative target to modulate the NFAT pathway
in cancer [33].
Because the NFAT family has shown pleiotropic functions in
various cancer types and tumor microenvironments, tumor-
speciﬁc or isoform-speciﬁc NFAT inhibitionwould be amore eﬃcient
cancer therapy approach. According to this concept, NFATs or NFAT
binding partners may serve as better drug targets. Many com-
pounds and drugs with this feature have been reported, including
digitoxin, zoledronic acid, and genistein [37,132,133]. These com-
pounds all have good antineoplastic effects in various tumor types,
but the molecular mechanisms have not been well studied.
Moreover, the modulation of downstream NFAT targets could be
an alternative approach for anti-cancer therapy. NFAT target genes,
such as COX-2, VEGFR and interleukins, are more readily speciﬁ-
cally targeted. Drugs targeting these genes are already in clinical
use, and a portion of cancer patients have beneﬁted from these drugs,
including non-steroidal anti-inﬂammatory drugs, sorafenib and
bevacizumab.
Finally, NFATs play pivotal roles in chemotherapy and targeted
therapy resistance, making use of NFAT inhibitor combination with
anti-cancer drugs a promising approach to overcome cancer drug
resistance. CsA is widely used in the clinic, and is also highly cost
effective. Accordingly, several clinical trials are under way, such as
dasatinib plus CsA in CML (NCT01426334) and selumetinib plus CsA
in colorectal cancer (NCT02188264).
Conclusions and perspectives
Since NFATs were originally described, many reports have indi-
cated that NFATs play an important role in cancer development and
treatment. NFATs have been shown to function in tumorigenesis,
proliferation, metastasis, drug resistance and the tumor microen-
vironment. It is now important to translate the basic research ﬁndings
into clinical anti-cancer therapeutics. Patients may gain clinical ben-
eﬁts from targeting NFATs or their up and down-streammolecules.
Furthermore, immunity and inﬂammation are essential compo-
nents of tumor development, and NFATs are at the intersection of
cancer and immunity. It will be important in the future to deter-
mine how the NFAT function is balanced between immunity and
cancer.
It remains unclear how the same NFAT isoform can have oppo-
site functions in different cancer types. The isoform-speciﬁc NFAT
function requires further investigation. In addition, whether the genes
encoding NFATs harbor mutations or ampliﬁcations in cancer is
unknown. Perhaps more likely, kinases or NFAT binding partners
that regulate NFATs may be dysfunctional in cancer. Therefore, ad-
dressing the issues discussed here will be pivotal in understanding
NFAT function in cancer and developing novel drugs against the NFAT
pathway.
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